药物性肝损伤的流行病学

李晓芸; 唐洁婷

doi:10.3969/j.issn.1001-5256.2021.11.002

药物性肝损伤的流行病学

DOI: 10.3969/j.issn.1001-5256.2021.11.002

李晓芸,
唐洁婷^,

上海交通大学医学院附属仁济医院，上海市消化疾病研究所，上海市脂肪性肝病诊治研究中心，上海 200001

基金项目:

上海交通大学医学院附属仁济医院临床科研创新培育基金 (PYI20-05)

详细信息

通信作者:
唐洁婷，start_tjt@msn.com

中图分类号: R575
计量
- 文章访问数: 1440
- HTML全文浏览量: 358
- PDF下载量: 384
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-31
- 录用日期: 2021-08-31
- 出版日期: 2021-11-20

Epidemiology of drug-induced liver injury

Xiaoyun LI,
Jieting TANG^,

Shanghai Research Center for Diagnosis and Treatment of Fatty Liver Disease, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China

Research funding:

Clinical Research Innovation Cultivation Fund of Renji hospital, Shanghai Jiao Tong University School of Medicine (PYI20-05)

摘要

摘要: 药物性肝损伤(DILI)的发病率逐年上升，目前已成为临床常见的肝病之一, 受到全世界范围的广泛关注。已知多种药物，包括中草药和膳食补充剂均可导致各种类型的急慢性肝损伤，重者可出现急性肝衰竭，导致死亡或接受肝移植。就DILI的全球流行情况及常见可疑药物的分布进行了阐述。
- 化学性与药物性肝损伤 /
- 流行病学研究 /
- 回顾性研究 /
- 前瞻性研究
Abstract: The incidence rate of drug-induced liver injury (DILI) is increasing year by year, and DILI has become one of the common liver diseases in clinical practice and has attracted the attention of the whole world. It is known that a variety of drugs, including Chinese herbal medicine and dietary supplements, can cause various types of acute or chronic liver injury, and acute liver failure may occur in severe cases, leading to death or liver transplantation. This article elaborates on the global prevalence of DILI and the distribution of common suspected drugs.
- Chemical and Drug-Induced Liver Injury /
- Epidemiologic Studies /
- Retrospective Studies /
- Prospective Studies

HTML全文

表 1 全球DILI流行病学现状

研究	研究类型	持续年份	年发病率	DILI总数 (例)	女性 (%)	主要年龄分布(岁)	慢性患者(%)	肝细胞型/ 胆汁淤积型/ 混合型(%)	病死率 (%)	主要诱发DILI药物(%)
冰岛	前瞻性	2010年—2011年	19.1/10万	96	56.25	40~59	7	42/32/26	1.04	抗菌药物(37.0)、HDS (16.0)、非甾体抗炎药(6.0)
法国	前瞻性	1997年—2000年	13.9/10万	34	64.7	≥50		47.1/20.6/26.5	5.88	抗感染药物(25.0)、精神药物(22.5)、降血脂药物(12.5)和非甾体抗炎药(10.0)
美国	前瞻性	2004年—2013年	2.7/10万成年人，特拉华州	899	59		18	54/23/23	6	抗菌药物(45.4)、HDS(16.1)、心血管系统药物(9.8)、中枢神经系统药物(9.1)
西班牙	前瞻性	1994年—2004年	3.42/10万	461	48.65	≥60	10.31	57.8/20.0/22.2	5.38	阿莫西林-克拉维酸(13.23)、结核病药物(6.95)、依溴替丁(4.93)
瑞典	回顾性	1970年—2004年	2.4/10万	784	57.7			52.2/26.3/21.5	9.18	抗生素(27.04)、非甾体抗炎药(4.85)、麻醉药(1.91)
印度	回顾性	1997年—2008年		313	42		0.32		17.3	结核病药物(57.8)、苯妥英钠(6.7)、奥氮平(5.4)、氨苯砜(5.4)
日本	回顾性	1997年—2006年		1676	57	50~69		59/20/21	0.4	抗生素(14.3)、精神药物和神经系统药物(10.1)、HDS(10.0)
中国	回顾性	2012年—2014年	23.80/10万	25 927	49.17	40~59	13	51.39/20.31/28.30	0.39	传统中药或HDS(26.81)、抗结核药物(21.99)、抗肿瘤药物或免疫调节剂(8.34)、抗感染药物(6.08)

下载: 导出CSV

参考文献(43)

[1]	CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966; quiz 967. DOI: 10.1038/ajg.2014.131.
[2]	ANDRADE RJ, CHALASANI N, BJÖRNSSON ES, et al. Drug-induced liver injury[J]. Nat Rev Dis Primers, 2019, 5(1): 58. DOI: 10.1038/s41572-019-0105-0.
[3]	Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002. 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
[4]	BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425. e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
[5]	SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857.
[6]	JICK H, DERBY LE, GARCíA RODRÍGUEZ LA, et al. Liver disease associated with diclofenac, naproxen, and piroxicam[J]. Pharmacotherapy, 1992, 12(3): 207-212.
[7]	DERBY LE, JICK H, HENRY DA, et al. Cholestatic hepatitis associated with flucloxacillin[J]. Med J Aust, 1993, 158(9): 596-600. DOI: 10.5694/j.1326-5377.1993.tb137624.x.
[8]	DERBY LE, JICK H, HENRY DA, et al. Erythromycin-associated cholestatic hepatitis[J]. Med J Aust, 1993, 158(9): 600-602. DOI: 10.5694/j.1326-5377.1993.tb137625.x.
[9]	GARCÍA RODRÍGUEZ LA, STRICKER BH, ZIMMERMAN HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid[J]. Arch Intern Med, 1996, 156(12): 1327-1332. DOI: 10.1001/archinte.1996.00440110099013.
[10]	GARCÍA RODRÍGUEZ LA, WALLANDER MA, STRICKER BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs[J]. Br J Clin Pharmacol, 1997, 43(2): 183-188. DOI: 10.1046/j.1365-2125.1997.05268.x.
[11]	JICK H, DERBY LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity[J]. Pharmacotherapy, 1995, 15(4): 428-432.
[12]	DERBY LE, GUTTHANN SP, JICK H, et al. Liver disorders in patients receiving chlorpromazine or isoniazid[J]. Pharmacotherapy, 1993, 13(4): 353-358.
[13]	GARCÍA RODRÍGUEZ LA, WILLIAMS R, DERBY LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors[J]. Arch Intern Med, 1994, 154(3): 311-316. DOI: 10.1001/archinte.1994.00420030117012.
[14]	de ABAJO FJ, MONTERO D, MADURGA M, et al. Acute and clinically relevant drug-induced liver injury: A population based case-control study[J]. Br J Clin Pharmacol, 2004, 58(1): 71-80. DOI: 10.1111/j.1365-2125.2004.02133.x.
[15]	VEGA M, VERMA M, BESWICK D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the state of delaware[J]. Drug Saf, 2017, 40(9): 783-787. DOI: 10.1007/s40264-017-0547-9.
[16]	AISO M, TAKIKAWA H, TSUJI K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan[J]. Hepatol Res, 2019, 49(1): 105-110. DOI: 10.1111/hepr.13288.
[17]	BAGHERI H, MICHEL F, LAPEYRE-MESTRE M, et al. Detection and incidence of drug-induced liver injuries in hospital: A prospective analysis from laboratory signals[J]. Br J Clin Pharmacol, 2000, 50(5): 479-484. DOI: 10.1046/j.1365-2125.2000.00282.x.
[18]	MEIER Y, CAVALLARO M, ROOS M, et al. Incidence of drug-induced liver injury in medical inpatients[J]. Eur J Clin Pharmacol, 2005, 61(2): 135-143. DOI: 10.1007/s00228-004-0888-z.
[19]	CANO-PANIAGUA A, AMARILES P, ANGULO N, et al. Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment[J]. Ann Hepatol, 2019, 18(3): 501-507. DOI: 10.1016/j.aohep.2018.11.008.
[20]	SUK KT, KIM DJ, KIM CH, et al. A prospective nationwide study of drug-induced liver injury in Korea[J]. Am J Gastroenterol, 2012, 107(9): 1380-1387. DOI: 10.1038/ajg.2012.138.
[21]	SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
[22]	de VALLE MB, AV KLINTEBERG V, ALEM N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic[J]. Aliment Pharmacol Ther, 2006, 24(8): 1187-1195. DOI: 10.1111/j.1365-2036.2006.03117.x.
[23]	BJÖRNSSON E, ISMAEL S, NEJDET S, et al. Severe jaundice in Sweden in the new millennium: Causes, investigations, treatment and prognosis[J]. Scand J Gastroenterol, 2003, 38(1): 86-94. DOI: 10.1080/00365520310000492.
[24]	VUPPALANCHI R, LIANGPUNSAKUL S, CHALASANI N. Etiology of new-onset jaundice: How often is it caused by idiosyncratic drug-induced liver injury in the United States?[J]. Am J Gastroenterol, 2007, 102(3): 558-562; quiz 693. DOI: 10.1111/j.1572-0241.2006.01019.x.
[25]	WEI G, BERGQUIST A, BROOMÉ U, et al. Acute liver failure in Sweden: Etiology and outcome[J]. J Intern Med, 2007, 262(3): 393-401. DOI: 10.1111/j.1365-2796.2007.01818.x.
[26]	OSTAPOWICZ G, FONTANA RJ, SCHIØDT FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J]. Ann Intern Med, 2002, 137(12): 947-954. DOI: 10.7326/0003-4819-137-12-200212170-00007.
[27]	REUBEN A, KOCH DG, LEE WM. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study[J]. Hepatology, 2010, 52(6): 2065-2076. DOI: 10.1002/hep.23937.
[28]	GOLDBERG DS, FORDE KA, CARBONARI DM, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system[J]. Gastroenterology, 2015, 148(7): 1353-1361. e3. DOI: 10.1053/j.gastro.2015.02.050.
[29]	GARCÍA RODRÍGUEZ LA, RUIGÓMEZ A, JICK H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom[J]. Pharmacotherapy, 1997, 17(4): 721-728.
[30]	CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006.
[31]	DEVARBHAVI H, DIERKHISING R, KREMERS WK, et al. Single-center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality[J]. Am J Gastroenterol, 2010, 105(11): 2396-2404. DOI: 10.1038/ajg.2010.287.
[32]	NAVARRO VJ, BARNHART H, BONKOVSKY HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network[J]. Hepatology, 2014, 60(4): 1399-1408. DOI: 10.1002/hep.27317.
[33]	TESCHKE R, EICKHOFF A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps[J]. Front Pharmacol, 2015, 6: 72. DOI: 10.3389/fphar.2015.00072.
[34]	HELMY A. Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome[J]. Aliment Pharmacol Ther, 2006, 23(1): 11-25. DOI: 10.1111/j.1365-2036.2006.02742.x.
[35]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
[36]	LUCENA MI, ANDRADE RJ, FERNÁNDEZ MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain[J]. Hepatology, 2006, 44(4): 850-856. DOI: 10.1002/hep.21324.
[37]	LUCENA MI, ANDRADE RJ, KAPLOWITZ N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex[J]. Hepatology, 2009, 49(6): 2001-2009. DOI: 10.1002/hep.22895.
[38]	MOLLESTON JP, FONTANA RJ, LOPEZ MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: Results from the DILIN prospective study[J]. J Pediatr Gastroenterol Nutr, 2011, 53(2): 182-189. DOI: 10.1097/MPG.0b013e31821d6cfd.
[39]	CHALASANI N, FONTANA RJ, BONKOVSKY HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135(6): 1924-1934, 1934. e1-4. DOI: 10.1053/j.gastro.2008.09.011.
[40]	LARREY D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Dis, 2002, 22(2): 145-155. DOI: 10.1055/s-2002-30105.
[41]	ANDRADE RJ, LUCENA MI, FERNÁNDEZ MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521. DOI: 10.1016/j.gastro.2005.05.006.
[42]	ORTEGA-ALONSO A, STEPHENS C, LUCENA MI, et al. Case characterization, clinical features and risk factors in drug-induced liver injury[J]. Int J Mol Sci, 2016, 17(5). DOI: 10.3390/ijms17050714.
[43]	DEVARBHAVI H. An update on drug-induced liver injury[J]. J Clin Exp Hepatol, 2012, 2(3): 247-259. DOI: 10.1016/j.jceh.2012.05.002.